764659-79-2Relevant articles and documents
Synthesis of (±)-Emtricitabine and (±)-Lamivudine by Chlorotrimethylsilane-Sodium Iodide-Promoted Vorbrüggen Glycosylation
Jamison, Timothy F.,Mear, Sarah Jane,Nguyen, Long V.,Rochford, Ashley J.
, (2022/02/07)
By simple combination of water and sodium iodide (NaI) with chlorotrimethylsilane (TMSCl), promotion of a Vorbrüggen glycosylation en route to essential HIV drugs emtricitabine (FTC) and lamivudine (3TC) is achieved. TMSCl-NaI in wet solvent (0.1 M water)
Preparation method of emtriva
-
Paragraph 0047; 0048; 0049, (2017/08/28)
The invention discloses a preparation method of emtriva. The preparation method comprises following steps: step A, in an alcoholic solvent I, an emtriva crude product and a halogen hydride are subjected to salt forming reaction so as to obtain a emtriva halogen acid salt, wherein the HPLC purity of the emtriva crude product is controlled to be 85.0% or higher, the halogen hydride is selected from hydrogen chloride, hydrogen bromide, or hydrogen iodide, and X is used for representing chlorine, bromine, or iodine; and step B, in an alcoholic solvent II, the emtriva halogen acid salt prepared in step A and an organic alkali are subjected to neutralization reaction so as to obtain emtriva, wherein X is used for representing chlorine, bromine, or iodine. The preparation method is simple in operation, simple in postprocessing, and high in yield; the purity of prepared emtriva is high; HPLC purity is higher than 99.60%; the content of the maximum single impurity is less than 0.10%; bulk pharmaceutical chemical standards are satisfied; production cost is low; and the preparation method is suitable for industrialized production.
Preparation process of emtricitabine intermediate
-
Paragraph 0074-0076; 0081; 0085; 0086; 0091; 0095, (2017/08/29)
The invention discloses a preparation process of an emtricitabine intermediate, namely (2R,5S)-5-(5'-fluoro-cytosine-1-yl)-1,3-dioxathiolane-2-carboxylic acid-L-menthyl ester shown as a structural formula (I). The preparation process comprises the following steps: (A) taking 5-fluorocytosine shown as a structural formula 7 as a raw material, and enabling the 5-fluorocytosine to react with N,N-dimethylformamide shown as a structural formula 20 and hexamethyldisilazane shown as a structural formula 8 to prepare 2-O-trimethylsilyl-4-N-[(N',N'-dimethyl)amino]methylene-5-fluorocytosine shown as a structural formula 21; (B) condensing the compound 21 and a chlorine substitute shown as a structural formula 6 to generate (2R,5S)-5-(4'-N-((N',' dimethyl)amino)methylene-5'-fluoro-cytosine-1-yl)-1,3-dioxathiolane-2-carboxylic acid-L-menthyl ester shown as a structural formula 22; and (C) hydrolyzing the compound 22 in an acidic solution to prepare the compound I. According to the preparation process, side reaction can be reduced so that the purity of a product is improved and the consumption of raw materials is reduced. The formula (I) is as shown in the specification.